ArticleThoracic cancer2025
Real-World Analysis of Treatment Patterns in Limited-Stage Small Cell Lung Cancer: Implications for Clinical Practice.
Article in Thoracic cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundUnresolved issues complicate treating limited-stage small-cell lung cancer (LS-SCLC). We conducted a real-world study analyzing LS-SCLC treatment patterns to address clinical needs.
methodsWe retrospectively enrolled patients with LS-SCLC treated at Peking Union Medical College Hospital between May 2008 and December 2023. Information was collected on clinicopathological features, cancer-related treatments, laboratory test results, and clinical and prognostic data. Kaplan-Meier survival analysis was performed to evaluate progression-free (PFS) and overall survival (OS). Cox regression models were used to assess the factors influencing survival.
resultsAmong the 203 patients with LS-SCLC, the median OS (mOS) was 28.8 months. Log-rank testing revealed significant mOS differences among radiotherapy timing groups (p = 0.031): concurrent chemoradiotherapy (cCRT) 30.1 months, sequential therapy 27.5 months, and no radiotherapy 21.7 months. Early cCRT showed a non-significant mOS trend advantage over late cCRT (38.3 vs. 29.5 months, p = 0.058). Prophylactic cranial irradiation (PCI) demonstrated comparable mOS (36.9 vs. 29.6 months, p = 0.27). Peripheral blood biomarkers (PBBs) lacked prognostic significance. Multivariate analysis identified Eastern Cooperative Oncology Group (ECOG) performance status (PS) > 1 (HR = 3.652, 95% CI 1.579-8.448; p = 0.002) and N2/N3 metastasis (N2: HR = 2.872, 95% CI 1.312-6.286, p = 0.008; N3: HR = 2.645, 95% CI 1.195-5.856, p = 0.016) as survival predictors. Sequential radiotherapy increased mortality risk versus early cCRT (HR = 1.701, 95% CI 1.125-2.573; p = 0.012).
conclusionsPerformance status and lymph node metastasis are prognostic factors for patients with LS-SCLC. cCRT improves the prognosis of LS-SCLC, with early cCRT providing a significant survival benefit and late cCRT being an acceptable option.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.